Spine BioPharma Reports Phase 3 Topline Results for SB-01 in Chronic Low Back Pain
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical…
United Therapeutics Launches $1 Billion Accelerated Stock Buyback Program
United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric…
Arrowhead’s Subsidiary Visirna Sells China Rights for Plozasiran to Sanofi
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape…
EC Approves CAR-T Therapy Using AGC Biologics’ Lentiviral Vectors
European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies,…
Altasciences and VoxCell Partner to Boost Preclinical Drug Development
Altasciences and VoxCell BioInnovation Forge Strategic Partnership to Revolutionize Preclinical Drug Development with 3D Bioprinted Human Tissue Models In a move poised to reshape the landscape of early-stage drug development,…
BeOne’s BGB-16673 Earns EMA PRIME Status for Waldenstrom’s Macroglobulinemia
BeOne Medicines Achieves Key Regulatory Milestone as EMA Grants PRIME Designation to BTK Degrader BGB-16673 for Waldenstrom’s Macroglobulinemia BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), an emerging global…
Bayer Raises 2025 Outlook, Adds U.S. Litigation Provisions
Bayer Raises Full-Year Outlook on Strong Pharma Performance, While Setting Aside €1.7 Billion for U.S. Litigation Risks Ahead of its scheduled second-quarter 2025 earnings release on August 6, Bayer AG…
Merck Finalizes Sale of Surface Solutions Business to GNMI
Merck Completes €665 Million Divestment of Surface Solutions Business to GNMI, Marking Strategic Realignment Toward Innovation-Focused Growth In a decisive move underscoring its strategic emphasis on core technological and scientific…
Actio Biosciences Secures FDA IND Clearance and Fast Track for ABS-1230 in KCNT1 Epilepsy
Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel…
AeroRx Reports Positive Phase 2a Results for Inhaled AERO-007 in COPD
AeroRx Therapeutics Reports Positive Phase 2a Results for Inhaled AERO-007, the First Nebulized LABA/LAMA Combination Therapy in Development for COPD AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in proprietary…
KKR Acquires HealthCare Royalty Partners to Boost Life Sciences Strategy
KKR Acquires Majority Stake in HealthCare Royalty Partners, Expanding Life Sciences Strategy and Biopharma Royalty Capabilities KKR & Co. Inc., one of the world’s foremost investment firms, has announced a…
Stallergenes Greer’s Palforzia® Spotlighted on Lifetime TV’s “The Balancing Act”
Stallergenes Greer Brings National Spotlight to Peanut Allergy Awareness with Palforzia® Segment on Lifetime TV’s “The Balancing Act” Stallergenes Greer, a global biopharmaceutical company and recognized leader in allergy immunotherapy…